Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

NCT06833112 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Ankylosing Spondylitis

Interventions

DRUG: Secukinumab
DRUG: Adalimumab

Sponsor

The Affiliated Hospital Of Guizhou Medical University